Corrigendum to: Low Expression MCEMP1 Promotes Lung Adenocarcinoma Progression and its Clinical Value.

Abstract

An error was noted on the page number 281, paragraph 1, of the article entitled "Low Expression MCEMP1 Promotes Lung Adenocarcinoma Progression and its Clinical Value" published in Current Cancer Drug Targets, 2025, 25(3), 281-293 [1], A phrase "continued=" yes"" was erroneously added which has now been removed. Details of the error and a correction are provided here. ORIGINAL: 1. INTRODUCTION It is worth noting that according to the 2020 Global Cancer Report statistics, LUAD has an incidence rate of 11.4%, ranking second after breast cancer (11.7%), but the mortality rate of LUAD is still the first, accounting for 18.0% of the total cancer deaths [1]. LUAD is the most common in non-small cell lung cancer (NSCLC), and LUAD is the main pathological subtype of NCSLC [2]. Because most patients with LUAD lack clear symptoms and signs in the early stage of the lesion, most of the lesions are in the middle and late stage, and most patients eventually die due to tumor recurrence, metastasis, and drug resistance, the long-term prognosis of patients with LUAD is still poor [3-6]. continued=" yes" Therefore, it has become one of the pathogen-esis and evolution mechanisms of LUAD and the more specific molecular targets, diagnosis and prognosis of LUAD at home and abroad. CORRECTED: 1. INTRODUCTION It is worth noting that according to the 2020 Global Cancer Report statistics, LUAD has an incidence rate of 11.4%, ranking second after breast cancer (11.7%), but the mortality rate of LUAD is still the first, accounting for 18.0% of the total cancer deaths [1]. LUAD is the most common in non-small cell lung cancer (NSCLC), and LUAD is the main pathological subtype of NCSLC [2]. Because most patients with LUAD lack clear symptoms and signs in the early stage of the lesion, most of the lesions are in the middle and late stage, and most patients eventually die due to tumor recurrence, metastasis, and drug resistance, the long-term prognosis of patients with LUAD is still poor [3-6]. Therefore, it has become one of the pathogenesis and evolution mechanisms of LUAD and the more specific molecular targets, diagnosis and prognosis of LUAD at home and abroad. We regret the error and apologize to readers. The original article can be found online at: https://www.eurekaselect.com/article/140008.